MedAvail (MDVLQ) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 08, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-36533
Entity Registrant Name	MEDAVAIL HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772394
Entity Address, Address Line One	4720 East Cotton Gin Loop,
Entity Address, Address Line Two	Suite 220
Entity Address, City or Town	Phoenix,
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85040
City Area Code	877
Local Phone Number	830-0826
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MDVL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,613,911
Entity Central Index Key	0001402479
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment flag	false
Document Period End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents		$ 14,359	$ 11,444
Restricted cash		676	676
Accounts receivable		292	404
Inventories		10,065	8,817
Prepaid expenses and other current assets		711	2,569
Current assets from discontinued operations		946	4,842
Total current assets		27,049	28,752
Property, plant and equipment, net		732	438
Intangible assets, net		657	451
Right-of-use assets		701	624
Other assets		40	30
Long-term assets from discontinued operations		729	2,837
Total assets		29,908	33,132
Current liabilities:
Accounts payable		796	818
Accrued liabilities		462	552
Accrued payroll and benefits		832	1,379
Deferred revenue		346	152
Current portion of lease obligations		208	246
Current liabilities from discontinued operations		1,512	2,794
Total current liabilities		4,156	5,941
Long-term debt, net		1,506	4,798
Long-term portion of lease obligations		550	441
Long-term liabilities from discontinued operations		651	1,128
Total liabilities		6,863	12,308
Commitments and contingencies (Note 10)
Stockholders' equity:
Common shares ($0.001 par value, 300,000,000 shares authorized, 1,613,870 and 1,603,394 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively)	[1]	2	2
Warrants		35,480	11,148
Additional paid-in-capital		257,318	256,308
Accumulated other comprehensive loss		(6,928)	(6,928)
Accumulated deficit		(262,827)	(239,706)
Total stockholders' equity		23,045	20,824
Total liabilities and stockholders' equity		$ 29,908	$ 33,132
[1]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical)		Jun. 30, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares
Statement of Financial Position [Abstract]
Common shares, par value (in USD per share) | $ / shares	[1]	$ 0.001	$ 0.001
Common shares, authorized (in shares)	[1]	300,000,000	300,000,000
Common shares, issued (in shares)	[1]	1,613,870	1,603,394
Common shares, outstanding (in shares)	[1]	1,613,870	1,603,394
[1]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue:
Total revenue		$ 405	$ 543	$ 1,025	$ 808
Cost of products sold and services:
Total cost of products sold and services		227	336	590	467
Other operating expenses:
General and administrative		4,365	5,053	9,325	10,488
Selling and marketing		122	55	254	155
Research and development		145	219	321	477
Total operating expense		4,632	5,327	9,900	11,120
Operating loss		(4,454)	(5,120)	(9,465)	(10,779)
Loss on issuance of warrants		0	0	(10,424)	0
(Loss) gain from change in fair value of warrant liabilities		(896)	0	2,149	0
Interest income		0	0	1	1
Interest expense		(146)	(273)	(315)	(524)
Loss before income taxes		(5,496)	(5,393)	(18,054)	(11,302)
Income tax expense		0	(24)	0	(24)
Net loss and comprehensive loss from continued operations		(5,496)	(5,417)	(18,054)	(11,326)
Discontinued operations:
Loss from discontinued operations		(295)	(6,301)	(5,067)	(13,414)
Net loss		$ (5,791)	$ (11,718)	$ (23,121)	$ (24,740)
Basic and diluted net loss per share:
Loss from continued operations - basic (in USD per share)	[1]	$ (3.06)	$ (3.91)	$ (10.61)	$ (11.05)
Loss from continued operations - diluted (in USD per share)	[1]	(3.06)	(3.91)	(10.61)	(11.05)
Loss from discontinued operations - basic (in USD per share)	[1]	(0.16)	(4.54)	(2.98)	(13.09)
Loss from discontinued operations - diluted (in USD per share)	[1]	$ (0.16)	$ (4.54)	$ (2.98)	$ (13.09)
Weighted average shares outstanding - basic (in shares)	[1]	1,798,245	1,387,134	1,702,360	1,024,800
Weighted average shares outstanding - diluted (in shares)	[1]	1,798,245	1,387,134	1,702,360	1,024,800
Hardware and subscription revenue
Revenue:
Total revenue		$ 127	$ 289	$ 431	$ 454
Cost of products sold and services:
Total cost of products sold and services		131	221	376	301
Service revenue
Revenue:
Total revenue		278	254	594	354
Cost of products sold and services:
Total cost of products sold and services		$ 96	$ 115	$ 214	$ 166
[1]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)	Jul. 31, 2023	Jul. 14, 2023	Jun. 14, 2023
Stock split, conversion ratio			0.0200
Subsequent Event
Stock split, conversion ratio	0.0200	0.0200

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands		Total		Private Placement	Common Shares		Common Shares Private Placement	Warrants	Warrants Private Placement	Additional Paid-in-Capital	[1]	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance at beginning of period (in shares) at Dec. 31, 2021	[1]				658,041
Balance at beginning of period at Dec. 31, 2021		$ 19,073			$ 0	[1]		$ 1,373		$ 216,718		$ (192,090)	$ (6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(24,740)										(24,740)
Issuance of common shares (in shares)	[1]				752,941		137
Issuance of common shares		37,201			$ 1	[1]				37,200
Issuance of warrants								7,503		(7,503)
Issuance of common shares under employee stock purchase plan (in shares)	[1]				1,080
Issuance of common shares under employee stock purchase plan		77								77
Share-based compensation		1,176								1,176
Balance at end of period (in shares) at Jun. 30, 2022	[1]				1,412,199
Balance at end of period at Jun. 30, 2022		32,787			$ 1	[1]		8,876		247,668		(216,830)	(6,928)
Balance at beginning of period (in shares) at Mar. 31, 2022	[1]				658,178
Balance at beginning of period at Mar. 31, 2022		6,615			$ 0	[1]		1,373		217,282		(205,112)	(6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(11,718)										(11,718)
Issuance of common shares (in shares)	[1]				752,941
Issuance of common shares		37,201			$ 1	[1]				37,200
Issuance of warrants		0						7,503		(7,503)
Issuance of common shares under employee stock purchase plan (in shares)	[1]				1,080
Issuance of common shares under employee stock purchase plan		77								77
Share-based compensation		612								612
Balance at end of period (in shares) at Jun. 30, 2022	[1]				1,412,199
Balance at end of period at Jun. 30, 2022		$ 32,787			$ 1	[1]		8,876		247,668		(216,830)	(6,928)
Balance at beginning of period (in shares) at Dec. 31, 2022		1,603,394	[2]		1,603,394	[1]
Balance at beginning of period at Dec. 31, 2022		$ 20,824			$ 2	[1]		11,148		256,308		(239,706)	(6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(23,121)										(23,121)
Issuance of common shares				$ 24,332					$ 24,332
Shares issued for vested RSUs (in shares)	[1]				9,702
Issuance of common shares under employee stock purchase plan (in shares)	[1]				774
Issuance of common shares under employee stock purchase plan		11								11
Share-based compensation		$ 999								999
Balance at end of period (in shares) at Jun. 30, 2023		1,613,870	[2]		1,613,870	[1]
Balance at end of period at Jun. 30, 2023		$ 23,045			$ 2	[1]		35,480		257,318		(262,827)	(6,928)
Balance at beginning of period (in shares) at Mar. 31, 2023	[1]				1,609,613
Balance at beginning of period at Mar. 31, 2023		4,169			$ 2	[1]		11,205		256,926		(257,036)	(6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(5,791)										(5,791)
Issuance of common shares				$ 24,275					$ 24,275
Shares issued for vested RSUs (in shares)	[1]				3,483
Issuance of common shares under employee stock purchase plan (in shares)	[1]				774
Issuance of common shares under employee stock purchase plan		11								11
Share-based compensation		$ 381								381
Balance at end of period (in shares) at Jun. 30, 2023		1,613,870	[2]		1,613,870	[1]
Balance at end of period at Jun. 30, 2023		$ 23,045			$ 2	[1]		$ 35,480		$ 257,318		$ (262,827)	$ (6,928)
[1]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.[2]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)	Jul. 31, 2023	Jul. 14, 2023	Jun. 14, 2023
Stock split, conversion ratio			0.0200
Subsequent Event
Stock split, conversion ratio	0.0200	0.0200

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (23,121)	$ (24,740)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	729	573
Amortization of intangible assets	68	295
Amortization of leased assets	518	384
Loss on disposal of net assets from discontinued operations	319	0
Loss on issuance of warrants	10,424	0
Gain from change in fair value of warrants	(2,149)	0
Credit losses on accounts receivable	91	59
Term loan discount amortization and interest accretion on debt	146	141
Share-based compensation expense	999	1,176
Changes in operating assets and liabilities:
Accounts receivable	880	(946)
Inventory	1,585	(2,380)
Prepaid expenses and other current assets	1,952	(1,185)
Accounts payable	(868)	700
Accrued liabilities	223	166
Accrued payroll and benefits	(1,300)	314
Deferred revenue	194	8
Operating lease liability due to cash payments	(279)	(279)
Net cash used in operating activities	(9,589)	(25,714)
Cash flows from investing activities:
Purchase of property, plant and equipment	0	(634)
Return (payment) of security deposits	51	(5)
Purchase of intangible assets and other assets	(109)	(1,087)
Net cash used in investing activities	(58)	(1,726)
Cash flows from financing activities:
Proceeds from issuance of warrants in private placement	15,999	37,201
Issuance of common shares upon exercise of employee stock purchase plan	11	77
Payment of debt issuance costs	(380)	0
Repayment of debt	(3,000)	0
Payments on finance lease obligations	(68)	(49)
Net cash provided by financing activities	12,562	37,229
Net increase in cash, cash equivalents and restricted cash	2,915	9,789
Cash, cash equivalents and restricted cash at beginning of period	12,120	20,089
Cash, cash equivalents and restricted cash at end of period	15,035	29,878
Supplemental cash flow information:
Cash paid for interest	242	376
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment	0	676
Purchase of property, plant and equipment in accounts payable	0	62
Purchases of intangible assets in accounts payable	151	0
Fair value of warrant issued upon closing of private placement	0	7,503
Reclassification of warrants from liability to equity classified	24,332	0
Lease liabilities arising from obtaining right of use assets:
Operating leases	0	206
Finance leases	$ 230	$ 73

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONS MedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation, is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter also has the ability to facilitate live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. Exit of Pharmacy Services and SpotRx On January 19, 2023, the Company announced a plan to exit the pharmacy services business to focus on its pharmacy technology business. In connection with its decision to exit the pharmacy services business, the Company initiated a reduction in force, in which employees of the pharmacy services business, representing at that time approximately 75% of the Company’s full-time employees, were terminated, effective January 18, 2023. The Company initiated the reduction in force to preserve capital and use its limited resources to pursue the pharmacy technology business. On January 20, 2023, the Company entered into an Asset Purchase and Sale Agreement, as amended, with German Dobson CVS, L.L.C., Garfield Beach CVS, L.L.C., Longs Drug Stores California, L.L.C., Woodward Detroit CVS, L.L.C. and Holiday CVS, L.L.C., or CVS, pursuant to which the Company agreed to sell to CVS certain assets, including pharmacy records, and inventory from SpotRx pharmacies located in Tucson and Phoenix, Arizona; Buena Park, Laguna Hills and San Fernando, California; Southfield, Michigan; and in Orlando and Tampa, Florida. The transaction closed on February 9, 2023, for a final purchase price of $2.9 million (subject to $0.1 million in fees and a $0.2 million indemnification holdback). Upon closing, the pharmacy assets purchased by CVS were transferred from the SpotRx pharmacies to nearby CVS pharmacy locations. Prior to the change in reporting for discontinued operations, the pharmacy services business comprised approximately 97% of the Company’s total revenues for the year ended December 31, 2022, and inventory from SpotRx pharmacies comprised approximately $3.0 million, or 9%, of total consolidated assets as of December 31, 2022. Pharmacy service business assets that were not sold to CVS have been or are expected to be primarily reabsorbed, settled, sold or abandoned. As of March 31, 2023, the Company had substantially completed its exit from the pharmacy services business. The accounting requirements for reporting the pharmacy services business as a discontinued operation were met during the three months ended March 31, 2023. Accordingly, the condensed consolidated financial statements and notes to the condensed consolidated financial statements reflect the results of the pharmacy service business as a discontinued operation for the periods presented. See Note 13 for additional information. Reverse Stock Split On June 14, 2023, the stockholders of the Company approved resolutions to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock, par value $0.001 per share, at a specific ratio within a range of 1-for-30 to 1-for-80, with the specific ratio to be determined by the Board of Directors in its sole discretion without further stockholder approval (the “Reverse Stock Split”). On July 14, 2023, the Board of Directors approved a Reverse Stock Split ratio of 1-for-50, such that every 50 shares of the Company’s common stock was combined into one share of common stock, effective at 5:00 p.m. Eastern Time on July 31, 2023. Except as otherwise noted, all references to common stock, preferred stock, restricted stock units, stock options, and warrants and all per share information throughout this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the Reverse Stock Split.

LIQUIDITY

LIQUIDITY	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY	LIQUIDITY The condensed consolidated financial statements for the three and six months ended June 30, 2023 and as of December 31, 2022, were prepared on the basis of a going concern which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. On March 9, 2023, the Company entered into a Securities Purchase Agreement with certain institutional investors, or the Investors, for the private placement of securities. Upon close of the transaction, the Company received gross proceeds from the offering of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from this offering to fund one-time costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. Pursuant to the offering, on March 13, 2023, the Company issued pre-funded warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.001 per share, or Pre-Funded Warrants, and on June 16, 2023, the Company issued Series A warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.38544 per share, or Series A Warrants. See Note 13. As of June 30, 2023, the Company had $15.0 million in cash and cash equivalents and restricted cash, and an accumulated deficit of $262.8 million. Furthermore, net cash used in operating activities for the six months ended June 30, 2023 and 2022 was $9.6 million and $25.7 million, respectively. Since inception through June 30, 2023, the Company has continually incurred losses from its operations, which have been financed primarily from net cash proceeds from sales of common stock and warrants in private placements, sales of redeemable preferred stock and debt. Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to the Company’s ability to continue as a going concern. If substantial doubt does exist, management should determine if there are plans in place which alleviate that doubt. As of December 31, 2021, and through the nine months ended September 30, 2022, the Company had identified substantial doubt as to the Company’s ability to continue as a going concern. As of December 31, 2022, there was no substantial doubt as to the Company's ability to continue as a going concern. During the first quarter of 2023, the Company raised capital in a private placement and reduced operating costs by exiting its pharmacy services business. As a result, after considering the Company's ongoing cash requirements to fund operations, management determined that the Company has sufficient financial resources to continue operations for one year from the date of issuance of these financial statements, with no substantial doubt as to the Company’s ability to continue as a going concern.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information, and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2022 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. The Company's critical accounting policies are those that are both most important to its financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company is not aware of any events or circumstances which would require update to its estimates or judgements as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2022 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission, or SEC, on April 14, 2023 and retrospectively revised and recast for discontinued operation presentation in the Company's Current Report on Form 8-K filed with the SEC on June 29, 2023. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated. As noted in Note 1, the Company substantially completed its exit from the pharmacy services business as of March 31, 2023. As a result, the Company has reported the operating results of its pharmacy services business in the loss from discontinued operations line in the condensed consolidated statements of operations for all periods presented. In addition, related assets and liabilities were reported as assets of discontinued operations and liabilities of discontinued operations in the condensed consolidated balance sheets for all periods presented. Unless otherwise noted, the discussion within these notes to the condensed consolidated financial statements relates to continuing operations comprised of the pharmacy technology business. See Note 13 for additional information on discontinued operations.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Recently Issued Accounting Standards Not Yet Adopted Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, or ASU 2022-03. The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated financial statements through the reporting date. Recently Adopted Accounting Standards Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments”, or ASU 2016-13, supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, or ASU 2018-19. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, and for fiscal years beginning after December 15, 2022 for all other public business entities and private companies, with early adoption permitted. Effective January 1, 2023, the Company adopted ASU No. 2016-13. The impact of adoption of ASU 2016-13 was not material to its consolidated financial statements.

LOSS PER SHARE

LOSS PER SHARE	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
LOSS PER SHARE	LOSS PER SHARE Basic loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period. The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding. After these warrants are exercised, the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 386 November 18, 2020 Outstanding 996,264 March 9, 2023 Outstanding

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Fair value measurements are categorized in one of the following three levels based on the lowest level input that is significant to the fair value measurement in its entirety: Level 1 - Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than quoted prices in active markets for identical assets or liabilities include: a. quoted prices for similar assets or liabilities in active markets; b. quoted prices for identical or similar assets or liabilities in inactive markets; c. inputs other than quoted prices that are observable for the asset or liability; d. inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3- Inputs to the valuation methodology are unobservable (i.e., supported by little or no market activity) and significant to the fair value measure. As of June 30, 2023 and December 31, 2022, there were no assets and liabilities accounted for at fair value on a reoccurring basis. However,on March 9, 2023, the Company entered into a Securities Purchase Agreement, or 2023 Purchase Agreement, with certain investors. Pursuant to the 2023 Purchase Agreement, the Company agreed to issue Pre-Funded Warrants and Series A Warrants. Consequently, the Company initially identified these warrants as liabilities and measured them at fair value on March 13, 2023, and subsequently remeasured the fair value of these warrant liabilities through June 14, 2023. The Company utilized the Black Scholes valuation methodology to determine the fair value of these warrants. The fair value of these warrants was classified as Level 3 with key Level 3 inputs of exercise price, term, and volatility. Any related loss or gain on the change in fair value of these warrant liabilities was recorded in the "Loss on issuance of warrants" and "(Loss) gain in change in fair value of warrant liabilities" line items within the condensed consolidated statements of operations and comprehensive loss. On June 14, 2023, the Company evaluated these warrant liabilities for equity criteria classification and consequently reclassified these warrant liabilities to equity. See Note 12, for further details regarding the Company's Pre-Funded and Series-A Warrants, the fair value measurement of these Warrants and subsequent equity classification. The following table presents the changes in the fair value of the Pre-Funded and Series A Warrants during the six months ended June 30, 2023: (in thousands) Pre-Funded Warrant Series-A Warrant Loss on Issuance of Warrants Gain from Change in Fair Value of Warrant Liabilities Measurement at March 13, 2023 $ 15,940 $ 10,484 $ (10,424) $ — Change in fair value $ (996) $ (1,153) — 2,149 Measurement at June 14, 2023 $ 14,944 $ 9,331

BALANCE SHEET AND OTHER INFORMA

BALANCE SHEET AND OTHER INFORMATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET AND OTHER INFORMATION	BALANCE SHEET AND OTHER INFORMATION Restricted Cash The Company considers cash to be restricted when withdrawal or general use is legally restricted. In 2021 pursuant to a Loan and Security Agreement with Silicon Valley Bank (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.7 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in cash and cash equivalents presented in the condensed consolidated statements of cash flows. Accounts Receivable Accounts receivable are primarily comprised of trade receivables presented net of allowance for doubtful accounts when estimable and present. The Company maintains an allowance for doubtful accounts based on its assessment of the collectability of amounts owed by customers. The allowance consists of known specific troubled accounts as well as an amount based on overall estimated potential uncollectible accounts receivable based on historical experience. As of June 30, 2023 and December 31, 2022, based upon its historical collections experience, the Company had no credit risk balances that required the Company to reserve an allowance for doubtful accounts. Inventories The following table presents detail of inventory balances: June 30, December 31, (in thousands) 2023 2022 Inventory: MedCenter hardware $ 7,924 $ 8,154 Spare parts 2,141 663 Total inventory $ 10,065 $ 8,817 MedCenter hardware recognized in hardware cost of products sold was $103 thousand and $176 thousand during the three months ended June 30, 2023 and 2022, respectively, and $314 thousand and $232 thousand during the six months ended June 30, 2023 and 2022, respectively. Prepaid Expenses and Other Current Assets The following table presents prepaid expenses and other current assets balances: June 30, December 31, (in thousands) 2023 2022 Prepaid expenses and other current assets: Prepaid MedCenter inventory $ — $ 1,359 Prepaid insurance 467 921 Other 244 289 Total prepaid expenses and other current assets $ 711 $ 2,569 Property, Plant and Equipment The following tables present property, plant and equipment balances: Estimated useful lives June 30, December 31, (in thousands) 2023 2022 Property, plant and equipment: MedCenter equipment 8 years $ 1,530 $ 1,357 IT equipment 1 - 3 years 2,002 1,908 Leasehold improvements lesser of useful life or term of lease 316 316 General plant and equipment 5 - 8 years 376 373 Office furniture and equipment 5 - 8 years 332 217 Vehicles 5 years 36 36 Construction-in-process 5 5 Total historical cost 4,597 4,212 Accumulated depreciation (3,865) (3,774) Total property, plant and equipment, net $ 732 $ 438 Depreciation expense of property and equipment was $57 thousand and $57 thousand for the three months ended June 30, 2023 and 2022, respectively, and $90 thousand and $117 thousand for the six months ended June 30, 2023 and 2022, respectively. Depreciation expense included in hardware cost of products sold was $2 thousand and $26 thousand for the three months ended June 30, 2023 and 2022, respectively, and $11 thousand and $52 thousand for the six months ended June 30, 2023 and 2022, respectively. Intangible Assets The following table presents intangible asset balances: June 30, December 31, (in thousands) 2023 2022 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 2,337 2,200 Website and mobile application 534 534 Other 123 — Total intangible assets 6,851 6,591 Accumulated amortization: Intellectual property (3,857) (3,857) Software (1,801) (1,749) Website and mobile application (534) (534) Other (2) — Total accumulated amortization (6,194) (6,140) Total intangible assets, net $ 657 $ 451 Amortization expense of intangible assets was $28 thousand and $20 thousand for the three months ended June 30, 2023 and 2022, respectively, and $54 thousand and $22 thousand for the six months ended June 30, 2023 and 2022, respectively, and are included in hardware cost of products sold and general and administrative operating expenses. Lessee Leases Balance sheet amounts for lease assets and leases liabilities are as follows: June 30, December 31, (in thousands) 2023 2022 Lease Assets: Operating $ 499 $ 620 Finance 202 4 Total lease assets $ 701 $ 624 Lease liabilities: Operating: Current $ 173 $ 241 Long-term 382 441 Finance: Current 35 5 Long-term 168 — Total lease liabilities $ 758 $ 687 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: June 30, December 31, 2023 2022 Finance leases: Weighted-average remaining lease term (years) 4.5 0.5 Weighted-average discount rate 11.5 % 6.0 % Operating leases: Weighted-average remaining lease term (years) 3.4 3.6 Weighted-average discount rate 6.1 % 7.3 % Maturities of operating leases liabilities are as follows: (in thousands) Remaining period in 2023 $ 135 2024 148 2025 152 2026 157 2027 37 Total operating lease payments 629 Less: present value discount (74) Total operating leases $ 555 Maturities of finance lease liabilities are as follows: (in thousands) Remaining period in 2023 $ 29 2024 58 2025 58 2026 58 2027 58 Total finance lease payments 261 Less: imputed interest (58) Total finance leases $ 203

DEBT

DEBT	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
DEBT	DEBT The following table presents debt balances: June 30, December 31, (in thousands) 2023 2022 Term loan $ 2,002 $ 5,182 Term loan issuance costs, net (496) (384) Long-term debt, net $ 1,506 $ 4,798 Maturities of debt liabilities are as follows: (in thousands) Remaining period in 2023 $ — 2024 668 2025 1,000 2026 334 Total debt $ 2,002 Term Loan The Term loan bears interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% (12.25% at June 30, 2023). The term loan matures on April 1, 2026. The remaining principal repayment will commence on May 1, 2024 in equal monthly installments of the outstanding Loan balance through the maturity date. First Amendment, Consent and Default Waiver to Loan and Security Agreement On February 10, 2023, the Company entered into the First Amendment, Consent and Default Waiver to Loan and Security Agreement or the Loan Amendment and Consent, with each of Silicon Valley Bank, a California corporation, and an authorized foreign bank under the Bank Act (Canada), and SVB Innovation Credit Fund VIII, L.P., a Delaware limited partnership, or together SVB. Among other matters, the Loan Amendment and Consent provides SVB’s consent to the sale of certain assets related to the Company’s pharmacy services business pursuant to the previously announced Asset Purchase Agreement. The Loan Amendment and Consent also provides that upon the closing of the asset sale, the Company would pay SVB $3.4 million, which includes $0.4 million of the Final Payment (as defined in the Loan Amendment and Consent) and prepayment of $3.0 million of Term Loan Advances (as defined in the Loan Amendment and Consent), with SVB waiving the prepayment premium due on all Term Loan Advances prepaid by the Company prior to February 10, 2023. The Loan Amendment and Consent also includes SVB's waiver of any legal action or enforcement of rights and remedies with respect to certain specified defaults arising prior to February 10, 2023. On February 10, 2023, in connection with the Loan Amendment and Consent, the Company issued warrants, or the SVB Warrants, to SVB for the purchase of up to an aggregate of 4 thousand shares of common stock at a per share exercise price of $16.37, with an expiration date of February 10, 2035. Pursuant to the terms of the SVB Warrants, the number of shares and the exercise price were adjusted as of June 16, 2023. See Note 12. SVB Letter Agreement On March 10, 2023, SVB, based in Santa Clara, California, was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. On March 10, 2023, the Federal Deposit Insurance Corporation (the “FDIC”) took control of SVB and created the National Bank of Santa Clara to hold the deposits of SVB after SVB was unable to continue their operations. On March 13, 2023, the Company was informed by SVB that the Company was still bound by the terms, conditions, and covenants of the Company’s Loan and Security Agreement with SVB, or the Loan Agreement, and the Loan Amendment and Consent. On March 29, 2023, the Company entered into a Letter Agreement, or Letter Agreement, with each of (a) Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB Successor, in its capacity as administrative agent and collateral agent, (b) SVB Successor, as a lender, and (c) SVB Innovation Credit Fund VIII, L.P., or SVB Capital, as a lender, and obtained a waiver for any event of default occurring prior to March 29, 2023, to include the year ended December 31, 2022. The Letter Agreement also amends the Loan Agreement to provide that the Company is only required to maintain on deposit at SVB Successor or its affiliates, at least 50% of the aggregate dollar value of all of the Company accounts at all financial institutions. As of June 30, 2023, the Company had approximately $9.7 million on deposit with SVB Successor and $5.3 million on deposit with another financial institution and was in compliance with all required covenants of the Loan Agreement. The Company continues to monitor the circumstances surrounding SVB and does not anticipate such circumstances will have a material impact on the Company's financial condition, operations, or on the Loan Agreement with SVB Successor. As of the date of filing this Quarterly Report on Form 10-Q, the Company has full access to and control over all of its cash and cash equivalents across all financial institutions.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company incurred minimal income tax expense for the three months ended June 30, 2023 and 2022, due to ongoing losses and minimum state income tax obligations. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses. As of June 30, 2023 and December 31, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation The Company is and, from time to time may in the future become, involved in legal proceedings, claims and litigation in the ordinary course of business. The Company has become subject to certain demands, and claims from former employees relating to the reduction in force the Company implemented in connection with the restructuring of the company and the disposition of its pharmacy services business. The Company intends to vigorously defend itself against such pending and threatened actions. The Company cannot determine a reasonable estimate of the maximum possible loss or range of loss for pending or threatened matters given that they are at various stages of the litigation process and each case is subject to the inherent uncertainties of litigation. In management’s opinion, based on currently available information, any potential loss resulting from the resolution of these matters is not expected to have a material adverse effect on the Company’s results of operations, financial position, or cash flows.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION Share-based Compensation The following table presents the Company's expense related to share-based compensation, in thousands: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Share-based compensation $ 381 $ 612 $ 999 $ 1,176 Expense remaining to be recognized for unvested option awards from the 2012, 2018, 2020 and 2022 plans as of June 30, 2023, was $1.5 million, which will be recognized on a weighted average basis over the next 2.0 years. Expense remaining to be recognized for unvested RSU awards as of June 30, 2023, was $0.9 million, which will be recognized on a weighted average basis over the next 1.5 years. The following table presents the Company's outstanding option awards activity during the six months ended June 30, 2023: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, at December 31, 2022 87,995 $ 94.64 $ 57.26 $ — Granted 43,637 15.25 11.66 1 Exercised/Released — — — — Expired (62) 622.69 372.66 — Forfeited (28,362) 95.49 53.27 — Outstanding, end of period, at June 30, 2023 103,208 $ 60.66 $ 39.03 9.11 $ — Vested and exercisable, at June 30, 2023 37,186 107.53 66.14 8.18 — Vested and unvested exercisable, at June 30, 2023 37,186 107.53 66.14 8.18 — Vested and expected to vest, at June 30, 2023 100,542 61.91 39.79 9.09 — The following table present outstanding RSU awards activity during the six months ended June 30, 2023: Number of Awards Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life (Years) Unvested outstanding, at December 31, 2022 47,531 $ — $ 65.30 — Granted — $ — $ — — Exercised/Released (9,702) $ 15.84 $ 77.02 — Cancelled/Forfeited (18,983) $ — $ 62.67 — Expired — $ — $ — — Unvested outstanding, at June 30, 2023 18,846 $ — $ 61.99 14.29 Vested outstanding shares at June 30, 2023 — $ — $ — — As of June 30, 2023 and December 31, 2022, there was an aggregate of 93 thousand and 46 thousand shares of common stock, respectively, available for grant under the 2020 Plan. As of June 30, 2023 and December 31, 2022, there was an aggregate of 22 thousand and 4 thousand shares of common stock, respectively, available for grant under the 2022 Inducement plan.

WARRANTS

WARRANTS	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
WARRANTS	WARRANTS The Company effected the Reverse Stock Split on July 31, 2023, pursuant to which every 50 shares of the Company’s common stock was combined into one share. The number of underlying shares and the exercise price of each of the Company’s warrants were proportionately adjusted to give effect to the Reverse Stock Split. The Reverse Stock Split had no effect on the accounting for the Company’s warrants. 2022 Warrants On March 30, 2022, the Company entered into a Securities Purchase Agreement with certain investors. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell in a private placement, or the 2022 Private Placement, up to 942 thousand shares of the Company’s common stock and warrants, or the 2022 Warrants, to purchase up to 470 thousand shares of common stock. The securities were sold at two closings at a price per share of $50.13. At the first closing on April 4, 2022, the Company sold 75.2 thousand shares of common stock and 2022 Warrants to purchase up to 376 thousand shares of common stock, for gross proceeds of $40.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on April 4, 2022 had a fair value of $9.2 million, a 5 year term and a per share exercise price of $62.50. A second and final closing occurred on July 1, 2022, at which the Company sold an additional 188 thousand shares of common stock and 2022 Warrants to purchase up to 94.0 thousand shares of common stock, for gross proceeds of $10.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on July 1, 2022 had a fair value of $4.5 million, a 5 year term and a per share exercise price of $62.50. None of the 2022 Warrants have been exercised or expired as of June 30, 2023 and December 31, 2022. The 2022 Warrants meet equity classification requirements and therefore are classified in our stockholders’ equity. 2023 SVB Warrants On February 10, 2023, as part of the First Amendment to the Loan and Security Agreement with Silicon Valley Bank ("SVB") (see Note 8), the Company issued warrants, or SVB Warrants, to purchase up to an aggregate of 4 thousand shares of common stock at a per share exercise price of $16.37, with an expiration date of February 10, 2035. The number of shares and the exercise price were subject to adjustment, or the Special Adjustment for Warrant Shares, upon the occurrence of the last closing of the Company’s next equity financing, as set forth in the SVB Warrants. On March 9, 2023, the Company entered into the 2023 Purchase Agreement, with certain institutional investors, pursuant to which the Company sold securities in a private placement at two closings that constituted the Company’s next equity financing within the meaning of the SVB Warrants. The first closing occurred o n March 13, 2023 and the second closing occurred on June 16, 2023. On June 16, 2023, pursuant the Special Adjustment for Warrant Shares, the number of shares of common stock underlying the SVB Warrants increased to 5.4 thousand and the per share exercise price decreased to $10.25. Upon the grant date, February 10, 2023, the fair value of the SVB Warrants was approximately $57 thousand measured using the Black-Scholes option pricing model. The SVB Warrants met equity classification requirement under ASC 815 - Derivative and Hedging, specifically due to the warrants having a limit on the number of shares the Company is required to deliver upon exercise and the warrant not including cash-settled top-off or make-whole provisions, as well as, other conditions. As such, the SVB Warrants met the equity classification requirements and are classified in the Company's stockholders' equity. None of the SVB Warrants have been exercised or expired as of June 30, 2023. The key input assumptions utilized in the valuation of the SVB Warrants were as follows: Grant date Market price $16.00 Exercise price $16.37 Term (Years) 12 Volatility 85% Risk Free Rate 3.68% 2023 Pre-Funded and Series A Warrants As noted above, on March 9, 2023, the Company entered into the 2023 Purchase Agreement with certain investors. Pursuant to the 2023 Purchase Agreement, the Company agreed to issue Pre-Funded Warrants and Series A Warrants. On March 13, 2023, at the first closing of the offering, the Company sold at a price of $16.06 per underlying share, Pre-Funded Warrants to purchase up to 996.3 thousand shares of common stock at an exercise price of $0.05 per share for total gross proceeds of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from the offering to fund costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. The number of Pre-Funded Warrants exercisable by investors was limited to 19.99% of the Company’s common stock outstanding immediately prior to the offering pursuant to a listing rule of The Nasdaq Stock Market, which required that the Company obtain stockholder approval of the issuance of shares above this 19.99% cap. The Pre-Funded Warrants were classified as a liability at issuance due to the need for the Company to obtain stockholder approval to settle the instruments in shares. On March 9, 2023, the Company also agreed to issue Series A Warrants to purchase up to 996.3 thousand shares of common stock with an exercise price of $19.27 per share, which was conditional upon the Company obtaining stockholder approval of the issuance. The Series A Warrants were also classified as a liability as the Company had an irrevocable obligation to obtain stockholder approval of the issuance of the Series A Warrant, and as such did not have sufficient shares to settle the obligation and consequently failed the equity classification requirements pending shareholder approval. On June 14, 2023, at its annual stockholders’ meeting, the Company obtained the requisite stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company issued the Series A Warrants on June 16, 2023. Upon grant, March 13, 2023, the fair value of the Pre-Funded Warrants and Series A Warrants was $15.9 million and $10.5 million, respectively. The Company recorded the $10.4 million difference between the offering proceeds and grant date fair value as a loss on issuance of warrants in the statement of operations and comprehensive loss. Subsequent to its grant date fair value measurement, and through June 14, 2023, the Company remeasured the warrants at fair value and recognized a gain from change in fair value of warrants on the statement of operations and comprehensive loss. As of June 14, 2023, the fair value of Pre-Funded Warrants and Series A Warrants was $14.9 million and $9.3 million, respectively. For the three and six months ended June 30, 2023, the Company recognized a loss of $0.9 million and gain of $2.1 million in fair value remeasurement of the Pre-Funded Warrants and Series A Warrants, respectively. Subsequent to the remeasurement of the Pre-Funded Warrants and Series A Warrants, the Company reassessed the liability classification of these warrants due to the Company obtaining on June 14, 2023, stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company determined that the Pre-Funded Warrants and Series A Warrants met the equity classification requirements, and the warrants were re-classified from liability to equity as of June 14, 2023. The fair values of the Pre-Funded Warrants and Series A Warrants were measured using the Black-Scholes option pricing model. As of the grant date and June 14, 2023, the key input assumptions utilized in the valuation of the Pre-funded Warrants were as follows: Grant date June 14, 2023 Market price $16.00 $15.00 Exercise price $0.05 $0.05 Term (Years)* IDF IDF Volatility 85% 82% Risk Free Rate 3.70% 3.90% *Warrant is outstanding until fully exercised; as such, the term was measured as indefinite. The key input assumptions utilized in the valuation of the Series A Warrants were as follows: Grant date June 14, 2023 Market price $16.00 $15.00 Exercise price $19.27 $19.27 Term (Years) 5 4.7 Volatility 85% 82% Risk Free Rate 3.68% 4.10% Reverse Stock Split On June 14, 2023, the stockholders of the Company approved a one-for-fifty reverse stock split of its outstanding shares of common stock. The reverse stock split became effective at 5:00 p.m. Eastern Time on July 31, 2023 (the “Effective Time”). At the Effective Time, every fifty issued and outstanding shares of the Company’s common stock were converted into one share of the Company’s common stock. The reverse split affected all the stockholders uniformly and did not affect any stockholder’s percentage ownership interests in the Company or proportionate voting power. Each common stockholder held the same percentage of the outstanding common stock immediately following the reverse split as that stockholder did immediately before the reverse split, except for minor adjustments as a result of the treatment of fractional shares. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). As a result, the number of common shares outstanding was reduced from 80,693,517 immediately before the Effective Time to 1,613,870. There was no change in the number of authorized shares of the Company's common stock or preferred stock, or to the par value per share of common stock due to the reverse stock split. All per share amounts and common shares outstanding for all periods presented in the unaudited consolidated financial statements have been adjusted retroactively to reflect the Company's one-for-fifty reverse stock split. After giving effect to the reverse stock split, the total number of shares of all classes of capital stock that the Company was authorized to issue was 310,000,000 shares, 300,000,000 shares of Common Stock, having a par value of $0.001, and 10,000,000 shares of Preferred Stock, having a par value of $0.001.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	6 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS As discussed in Note 1 – Nature of Operations – the exit from our pharmacy services business was substantially completed as of March 31, 2023. The pharmacy services business previously was a reportable segment and the exit represents a strategic shift in the Company going forward. Accordingly, with the sale or disposition of its retail pharmacy assets and exit from the pharmacy services business, this transaction meets the accounting requirements for reporting as discontinued operations under ASC 205-20-50 for all periods presented. The following table summarizes the major income and expense line items from discontinued operations as reported in the condensed consolidated statements of operations and comprehensive loss: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2023 2022 2023 2022 Revenue: Pharmacy revenue $ — $ 10,641 $ 3,834 $ 19,490 Total revenue — 10,641 3,834 19,490 Cost of products sold and services: Pharmacy cost of products sold — 9,931 3,581 18,412 Total cost of products sold and services — 9,931 3,581 18,412 Operating expense: Pharmacy operations 157 3,450 1,883 7,170 General and administrative 141 1,242 711 2,560 Selling and marketing — 2,253 845 4,457 Research and development — 63 — 299 Total operating expense 298 7,008 3,439 14,486 Operating loss (298) (6,298) (3,186) (13,408) Loss from sale and disposition of net assets, and reorganization expenses, net — — (1,885) — Interest expense 3 (3) 4 (6) Loss from discontinued operations $ (295) $ (6,301) $ (5,067) $ (13,414) Cash used by operating activities by the pharmacy services business totaled $987 thousand and $14.4 million for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash provided by (used in) investing activities from the pharmacy services business totaled $212 thousand and $(428) thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash used in financing activities from the pharmacy services business totaled $47 thousand and $41 thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. Depreciation and amortization expense of the pharmacy services business totaled $895 thousand and $673 thousand for the six months ended June 30, 2023 and June 30, 2022, respectively. The condensed consolidated statements of cash flows included $319 thousand loss on disposal of net assets from discontinued operations, which comprised of losses related to net realizable value adjustments to right of use assets related to leases and prepaid assets, and abandonment of certain property, plant, and equipment related to our discontinued operations. The following table summarizes the major classes of assets and liabilities of the retail pharmacy business as reported on the condensed consolidated balance sheets: (in thousands) June 30, 2023 December 31, 2022 Carrying amounts of major classed of assets included as part of discontinued operations: Accounts receivable, net $ 946 $ 1,805 Prepaid expenses and other current assets — 94 Inventories — 2,943 Total current assets from discontinued operations $ 946 $ 4,842 Intangible assets, net $ — $ 14 Property plant and equipment, net — 1,194 Right-of-use assets 622 1,461 Other assets 107 168 Total long-term assets from discontinued operations $ 729 $ 2,837 Total long-term assets from discontinued operations Accounts payable $ 162 $ 857 Accrued liabilities 954 641 Accrued payroll and benefits 81 834 Current portion of lease obligations 315 462 Total current liabilities from discontinued operations $ 1,512 $ 2,794 Long-term portion of lease obligations $ 651 $ 1,128 Total long-term liabilities from discontinued operations $ 651 $ 1,128

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
STOCKHOLDERS' EQUITY	WARRANTS The Company effected the Reverse Stock Split on July 31, 2023, pursuant to which every 50 shares of the Company’s common stock was combined into one share. The number of underlying shares and the exercise price of each of the Company’s warrants were proportionately adjusted to give effect to the Reverse Stock Split. The Reverse Stock Split had no effect on the accounting for the Company’s warrants. 2022 Warrants On March 30, 2022, the Company entered into a Securities Purchase Agreement with certain investors. Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell in a private placement, or the 2022 Private Placement, up to 942 thousand shares of the Company’s common stock and warrants, or the 2022 Warrants, to purchase up to 470 thousand shares of common stock. The securities were sold at two closings at a price per share of $50.13. At the first closing on April 4, 2022, the Company sold 75.2 thousand shares of common stock and 2022 Warrants to purchase up to 376 thousand shares of common stock, for gross proceeds of $40.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on April 4, 2022 had a fair value of $9.2 million, a 5 year term and a per share exercise price of $62.50. A second and final closing occurred on July 1, 2022, at which the Company sold an additional 188 thousand shares of common stock and 2022 Warrants to purchase up to 94.0 thousand shares of common stock, for gross proceeds of $10.0 million before deducting placement agent commissions and other offering expenses. The 2022 Warrants issued on July 1, 2022 had a fair value of $4.5 million, a 5 year term and a per share exercise price of $62.50. None of the 2022 Warrants have been exercised or expired as of June 30, 2023 and December 31, 2022. The 2022 Warrants meet equity classification requirements and therefore are classified in our stockholders’ equity. 2023 SVB Warrants On February 10, 2023, as part of the First Amendment to the Loan and Security Agreement with Silicon Valley Bank ("SVB") (see Note 8), the Company issued warrants, or SVB Warrants, to purchase up to an aggregate of 4 thousand shares of common stock at a per share exercise price of $16.37, with an expiration date of February 10, 2035. The number of shares and the exercise price were subject to adjustment, or the Special Adjustment for Warrant Shares, upon the occurrence of the last closing of the Company’s next equity financing, as set forth in the SVB Warrants. On March 9, 2023, the Company entered into the 2023 Purchase Agreement, with certain institutional investors, pursuant to which the Company sold securities in a private placement at two closings that constituted the Company’s next equity financing within the meaning of the SVB Warrants. The first closing occurred o n March 13, 2023 and the second closing occurred on June 16, 2023. On June 16, 2023, pursuant the Special Adjustment for Warrant Shares, the number of shares of common stock underlying the SVB Warrants increased to 5.4 thousand and the per share exercise price decreased to $10.25. Upon the grant date, February 10, 2023, the fair value of the SVB Warrants was approximately $57 thousand measured using the Black-Scholes option pricing model. The SVB Warrants met equity classification requirement under ASC 815 - Derivative and Hedging, specifically due to the warrants having a limit on the number of shares the Company is required to deliver upon exercise and the warrant not including cash-settled top-off or make-whole provisions, as well as, other conditions. As such, the SVB Warrants met the equity classification requirements and are classified in the Company's stockholders' equity. None of the SVB Warrants have been exercised or expired as of June 30, 2023. The key input assumptions utilized in the valuation of the SVB Warrants were as follows: Grant date Market price $16.00 Exercise price $16.37 Term (Years) 12 Volatility 85% Risk Free Rate 3.68% 2023 Pre-Funded and Series A Warrants As noted above, on March 9, 2023, the Company entered into the 2023 Purchase Agreement with certain investors. Pursuant to the 2023 Purchase Agreement, the Company agreed to issue Pre-Funded Warrants and Series A Warrants. On March 13, 2023, at the first closing of the offering, the Company sold at a price of $16.06 per underlying share, Pre-Funded Warrants to purchase up to 996.3 thousand shares of common stock at an exercise price of $0.05 per share for total gross proceeds of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from the offering to fund costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. The number of Pre-Funded Warrants exercisable by investors was limited to 19.99% of the Company’s common stock outstanding immediately prior to the offering pursuant to a listing rule of The Nasdaq Stock Market, which required that the Company obtain stockholder approval of the issuance of shares above this 19.99% cap. The Pre-Funded Warrants were classified as a liability at issuance due to the need for the Company to obtain stockholder approval to settle the instruments in shares. On March 9, 2023, the Company also agreed to issue Series A Warrants to purchase up to 996.3 thousand shares of common stock with an exercise price of $19.27 per share, which was conditional upon the Company obtaining stockholder approval of the issuance. The Series A Warrants were also classified as a liability as the Company had an irrevocable obligation to obtain stockholder approval of the issuance of the Series A Warrant, and as such did not have sufficient shares to settle the obligation and consequently failed the equity classification requirements pending shareholder approval. On June 14, 2023, at its annual stockholders’ meeting, the Company obtained the requisite stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company issued the Series A Warrants on June 16, 2023. Upon grant, March 13, 2023, the fair value of the Pre-Funded Warrants and Series A Warrants was $15.9 million and $10.5 million, respectively. The Company recorded the $10.4 million difference between the offering proceeds and grant date fair value as a loss on issuance of warrants in the statement of operations and comprehensive loss. Subsequent to its grant date fair value measurement, and through June 14, 2023, the Company remeasured the warrants at fair value and recognized a gain from change in fair value of warrants on the statement of operations and comprehensive loss. As of June 14, 2023, the fair value of Pre-Funded Warrants and Series A Warrants was $14.9 million and $9.3 million, respectively. For the three and six months ended June 30, 2023, the Company recognized a loss of $0.9 million and gain of $2.1 million in fair value remeasurement of the Pre-Funded Warrants and Series A Warrants, respectively. Subsequent to the remeasurement of the Pre-Funded Warrants and Series A Warrants, the Company reassessed the liability classification of these warrants due to the Company obtaining on June 14, 2023, stockholder approval for removal of the exercise cap on the Pre-Funded Warrants and for issuance of the Series A Warrants. The Company determined that the Pre-Funded Warrants and Series A Warrants met the equity classification requirements, and the warrants were re-classified from liability to equity as of June 14, 2023. The fair values of the Pre-Funded Warrants and Series A Warrants were measured using the Black-Scholes option pricing model. As of the grant date and June 14, 2023, the key input assumptions utilized in the valuation of the Pre-funded Warrants were as follows: Grant date June 14, 2023 Market price $16.00 $15.00 Exercise price $0.05 $0.05 Term (Years)* IDF IDF Volatility 85% 82% Risk Free Rate 3.70% 3.90% *Warrant is outstanding until fully exercised; as such, the term was measured as indefinite. The key input assumptions utilized in the valuation of the Series A Warrants were as follows: Grant date June 14, 2023 Market price $16.00 $15.00 Exercise price $19.27 $19.27 Term (Years) 5 4.7 Volatility 85% 82% Risk Free Rate 3.68% 4.10% Reverse Stock Split On June 14, 2023, the stockholders of the Company approved a one-for-fifty reverse stock split of its outstanding shares of common stock. The reverse stock split became effective at 5:00 p.m. Eastern Time on July 31, 2023 (the “Effective Time”). At the Effective Time, every fifty issued and outstanding shares of the Company’s common stock were converted into one share of the Company’s common stock. The reverse split affected all the stockholders uniformly and did not affect any stockholder’s percentage ownership interests in the Company or proportionate voting power. Each common stockholder held the same percentage of the outstanding common stock immediately following the reverse split as that stockholder did immediately before the reverse split, except for minor adjustments as a result of the treatment of fractional shares. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). As a result, the number of common shares outstanding was reduced from 80,693,517 immediately before the Effective Time to 1,613,870. There was no change in the number of authorized shares of the Company's common stock or preferred stock, or to the par value per share of common stock due to the reverse stock split. All per share amounts and common shares outstanding for all periods presented in the unaudited consolidated financial statements have been adjusted retroactively to reflect the Company's one-for-fifty reverse stock split. After giving effect to the reverse stock split, the total number of shares of all classes of capital stock that the Company was authorized to issue was 310,000,000 shares, 300,000,000 shares of Common Stock, having a par value of $0.001, and 10,000,000 shares of Preferred Stock, having a par value of $0.001.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Reverse Stock Split On June 14, 2023, the stockholders of the Company approved resolutions to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock, par value of $0.001 per share, at a specific ratio within a range of 1-for-30 to 1-for-80, with the specific ratio to be fixed within this range to be determined by the Board of Directors in its sole discretion without further loss per share approval. On July 14, 2023, the Board of Directors approved a ratio of 1-for-50, such that every 50 shares of the Company’s common stock were combined into one share of its common stock at 5:00 p.m. Eastern Time on July 31, 2023.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information, and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2022 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. The Company's critical accounting policies are those that are both most important to its financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company is not aware of any events or circumstances which would require update to its estimates or judgements as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2022 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission, or SEC, on April 14, 2023 and retrospectively revised and recast for discontinued operation presentation in the Company's Current Report on Form 8-K filed with the SEC on June 29, 2023.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated. As noted in Note 1, the Company substantially completed its exit from the pharmacy services business as of March 31, 2023. As a result, the Company has reported the operating results of its pharmacy services business in the loss from discontinued operations line in the condensed consolidated statements of operations for all periods presented. In addition, related assets and liabilities were reported as assets of discontinued operations and liabilities of discontinued operations in the condensed consolidated balance sheets for all periods presented. Unless otherwise noted, the discussion within these notes to the condensed consolidated financial statements relates to continuing operations comprised of the pharmacy technology business. See Note 13 for additional information on discontinued operations.
Recently Issued Accounting Standards Not Yet Adopted and Recently Adopted Accounting Standards	Recently Issued Accounting Standards Not Yet Adopted Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, or ASU 2022-03. The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated financial statements through the reporting date. Recently Adopted Accounting Standards Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments”, or ASU 2016-13, supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, or ASU 2018-19. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, and for fiscal years beginning after December 15, 2022 for all other public business entities and private companies, with early adoption permitted. Effective January 1, 2023, the Company adopted ASU No. 2016-13. The impact of adoption of ASU 2016-13 was not material to its consolidated financial statements.

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Warrants Included in Earnings per Share	The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding. After these warrants are exercised, the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 386 November 18, 2020 Outstanding 996,264 March 9, 2023 Outstanding

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Changes in the Fair Value of the Pre-funded and Series a Warrants	The following table presents the changes in the fair value of the Pre-Funded and Series A Warrants during the six months ended June 30, 2023: (in thousands) Pre-Funded Warrant Series-A Warrant Loss on Issuance of Warrants Gain from Change in Fair Value of Warrant Liabilities Measurement at March 13, 2023 $ 15,940 $ 10,484 $ (10,424) $ — Change in fair value $ (996) $ (1,153) — 2,149 Measurement at June 14, 2023 $ 14,944 $ 9,331

BALANCE SHEET AND OTHER INFOR_2

BALANCE SHEET AND OTHER INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	The following table presents detail of inventory balances: June 30, December 31, (in thousands) 2023 2022 Inventory: MedCenter hardware $ 7,924 $ 8,154 Spare parts 2,141 663 Total inventory $ 10,065 $ 8,817
Schedule of Prepaid Expenses and Other Current Assets	The following table presents prepaid expenses and other current assets balances: June 30, December 31, (in thousands) 2023 2022 Prepaid expenses and other current assets: Prepaid MedCenter inventory $ — $ 1,359 Prepaid insurance 467 921 Other 244 289 Total prepaid expenses and other current assets $ 711 $ 2,569
Schedule of Property, Plant and Equipment and Useful Lives	The following tables present property, plant and equipment balances: Estimated useful lives June 30, December 31, (in thousands) 2023 2022 Property, plant and equipment: MedCenter equipment 8 years $ 1,530 $ 1,357 IT equipment 1 - 3 years 2,002 1,908 Leasehold improvements lesser of useful life or term of lease 316 316 General plant and equipment 5 - 8 years 376 373 Office furniture and equipment 5 - 8 years 332 217 Vehicles 5 years 36 36 Construction-in-process 5 5 Total historical cost 4,597 4,212 Accumulated depreciation (3,865) (3,774) Total property, plant and equipment, net $ 732 $ 438
Schedule of Intangible Assets	The following table presents intangible asset balances: June 30, December 31, (in thousands) 2023 2022 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 2,337 2,200 Website and mobile application 534 534 Other 123 — Total intangible assets 6,851 6,591 Accumulated amortization: Intellectual property (3,857) (3,857) Software (1,801) (1,749) Website and mobile application (534) (534) Other (2) — Total accumulated amortization (6,194) (6,140) Total intangible assets, net $ 657 $ 451
Schedule of Lease Assets and Liabilities	Balance sheet amounts for lease assets and leases liabilities are as follows: June 30, December 31, (in thousands) 2023 2022 Lease Assets: Operating $ 499 $ 620 Finance 202 4 Total lease assets $ 701 $ 624 Lease liabilities: Operating: Current $ 173 $ 241 Long-term 382 441 Finance: Current 35 5 Long-term 168 — Total lease liabilities $ 758 $ 687 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: June 30, December 31, 2023 2022 Finance leases: Weighted-average remaining lease term (years) 4.5 0.5 Weighted-average discount rate 11.5 % 6.0 % Operating leases: Weighted-average remaining lease term (years) 3.4 3.6 Weighted-average discount rate 6.1 % 7.3 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating leases liabilities are as follows: (in thousands) Remaining period in 2023 $ 135 2024 148 2025 152 2026 157 2027 37 Total operating lease payments 629 Less: present value discount (74) Total operating leases $ 555
Schedule of Maturities of Finance Lease Liabilities	Maturities of finance lease liabilities are as follows: (in thousands) Remaining period in 2023 $ 29 2024 58 2025 58 2026 58 2027 58 Total finance lease payments 261 Less: imputed interest (58) Total finance leases $ 203

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Debt	The following table presents debt balances: June 30, December 31, (in thousands) 2023 2022 Term loan $ 2,002 $ 5,182 Term loan issuance costs, net (496) (384) Long-term debt, net $ 1,506 $ 4,798
Schedule of Maturities of Debt Liabilities	Maturities of debt liabilities are as follows: (in thousands) Remaining period in 2023 $ — 2024 668 2025 1,000 2026 334 Total debt $ 2,002

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Compensation Expense	The following table presents the Company's expense related to share-based compensation, in thousands: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Share-based compensation $ 381 $ 612 $ 999 $ 1,176
Schedule of Outstanding Option Awards Activity	The following table presents the Company's outstanding option awards activity during the six months ended June 30, 2023: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, at December 31, 2022 87,995 $ 94.64 $ 57.26 $ — Granted 43,637 15.25 11.66 1 Exercised/Released — — — — Expired (62) 622.69 372.66 — Forfeited (28,362) 95.49 53.27 — Outstanding, end of period, at June 30, 2023 103,208 $ 60.66 $ 39.03 9.11 $ — Vested and exercisable, at June 30, 2023 37,186 107.53 66.14 8.18 — Vested and unvested exercisable, at June 30, 2023 37,186 107.53 66.14 8.18 — Vested and expected to vest, at June 30, 2023 100,542 61.91 39.79 9.09 —
Schedule of Outstanding RSU Awards Activity	The following table present outstanding RSU awards activity during the six months ended June 30, 2023: Number of Awards Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life (Years) Unvested outstanding, at December 31, 2022 47,531 $ — $ 65.30 — Granted — $ — $ — — Exercised/Released (9,702) $ 15.84 $ 77.02 — Cancelled/Forfeited (18,983) $ — $ 62.67 — Expired — $ — $ — — Unvested outstanding, at June 30, 2023 18,846 $ — $ 61.99 14.29 Vested outstanding shares at June 30, 2023 — $ — $ — —

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of Assumptions in Valuation of Awards Other than Options Granted and Warrant Issued	The key input assumptions utilized in the valuation of the SVB Warrants were as follows: Grant date Market price $16.00 Exercise price $16.37 Term (Years) 12 Volatility 85% Risk Free Rate 3.68% Grant date June 14, 2023 Market price $16.00 $15.00 Exercise price $0.05 $0.05 Term (Years)* IDF IDF Volatility 85% 82% Risk Free Rate 3.70% 3.90% *Warrant is outstanding until fully exercised; as such, the term was measured as indefinite. The key input assumptions utilized in the valuation of the Series A Warrants were as follows: Grant date June 14, 2023 Market price $16.00 $15.00 Exercise price $19.27 $19.27 Term (Years) 5 4.7 Volatility 85% 82% Risk Free Rate 3.68% 4.10%

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	6 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Income, Assets and Liabilities from Discontinued Operations	The following table summarizes the major income and expense line items from discontinued operations as reported in the condensed consolidated statements of operations and comprehensive loss: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2023 2022 2023 2022 Revenue: Pharmacy revenue $ — $ 10,641 $ 3,834 $ 19,490 Total revenue — 10,641 3,834 19,490 Cost of products sold and services: Pharmacy cost of products sold — 9,931 3,581 18,412 Total cost of products sold and services — 9,931 3,581 18,412 Operating expense: Pharmacy operations 157 3,450 1,883 7,170 General and administrative 141 1,242 711 2,560 Selling and marketing — 2,253 845 4,457 Research and development — 63 — 299 Total operating expense 298 7,008 3,439 14,486 Operating loss (298) (6,298) (3,186) (13,408) Loss from sale and disposition of net assets, and reorganization expenses, net — — (1,885) — Interest expense 3 (3) 4 (6) Loss from discontinued operations $ (295) $ (6,301) $ (5,067) $ (13,414) The following table summarizes the major classes of assets and liabilities of the retail pharmacy business as reported on the condensed consolidated balance sheets: (in thousands) June 30, 2023 December 31, 2022 Carrying amounts of major classed of assets included as part of discontinued operations: Accounts receivable, net $ 946 $ 1,805 Prepaid expenses and other current assets — 94 Inventories — 2,943 Total current assets from discontinued operations $ 946 $ 4,842 Intangible assets, net $ — $ 14 Property plant and equipment, net — 1,194 Right-of-use assets 622 1,461 Other assets 107 168 Total long-term assets from discontinued operations $ 729 $ 2,837 Total long-term assets from discontinued operations Accounts payable $ 162 $ 857 Accrued liabilities 954 641 Accrued payroll and benefits 81 834 Current portion of lease obligations 315 462 Total current liabilities from discontinued operations $ 1,512 $ 2,794 Long-term portion of lease obligations $ 651 $ 1,128 Total long-term liabilities from discontinued operations $ 651 $ 1,128

NATURE OF OPERATIONS (Details)

NATURE OF OPERATIONS (Details) $ / shares in Units, $ in Thousands						12 Months Ended
	Jul. 31, 2023 $ / shares	Jul. 14, 2023	Jun. 14, 2023 $ / shares	Feb. 09, 2023 USD ($)	Jan. 18, 2023	Dec. 31, 2022 USD ($) $ / shares		Jun. 30, 2023 USD ($) $ / shares
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Reduction of full-time employees, percentage					75%
Sale price				$ 2,900
Fees				100
Holdback				$ 200
Inventories						$ 8,817		$ 10,065
Common shares, par value (in USD per share) | $ / shares			$ 0.001			$ 0.001	[1]	$ 0.001	[1]
Stock split, conversion ratio			0.0200
Subsequent Event
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Common shares, par value (in USD per share) | $ / shares	$ 0.001
Stock split, conversion ratio	0.0200	0.0200
Minimum
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Stock split, conversion ratio			0.0333
Maximum
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Stock split, conversion ratio			0.0125
Pharmacy Services Business | Revenue | Product Concentration Risk
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Concentration risk, percentage						97%
Inventory From SpotRx Pharmacies
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Inventories						$ 3,000
Inventory From SpotRx Pharmacies | Assets, Total | Product Concentration Risk
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Concentration risk, percentage						9%
[1]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

LIQUIDITY (Details)

LIQUIDITY (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Mar. 09, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 16, 2023	Mar. 13, 2023	Dec. 31, 2022	Mar. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Proceeds from issuance of warrants in private placement		$ 15,999	$ 37,201
Cash and cash equivalents, including restricted cash		15,035	29,878			$ 12,120		$ 20,089
Accumulated deficit		262,827				$ 239,706
Net cash used in operating activities		$ 9,589	$ 25,714
Pre-Funded Warrant Liability
Debt Instrument [Line Items]
Proceeds from issuance of warrants in private placement	$ 16,000
Number of shares called by warrants (in shares)	996,300
Exercise price of warrants issued (in USD per share)	$ 0.05
Series-A Warrant Liability
Debt Instrument [Line Items]
Number of shares called by warrants (in shares)	996,300
Exercise price of warrants issued (in USD per share)	$ 19.27
Private Placement
Debt Instrument [Line Items]
Proceeds from issuance of warrants in private placement	$ 16,000
Number of shares called by warrants (in shares)							470,000
Private Placement | Pre-Funded Warrant Liability
Debt Instrument [Line Items]
Number of shares called by warrants (in shares)					49,813,198
Exercise price of warrants issued (in USD per share)					$ 0.001
Private Placement | Series-A Warrant Liability
Debt Instrument [Line Items]
Number of shares called by warrants (in shares)				49,813,198
Exercise price of warrants issued (in USD per share)				$ 0.38544

LOSS PER SHARE - Warrants Inclu

LOSS PER SHARE - Warrants Included in Earnings per Share (Details)	6 Months Ended
	Jun. 30, 2023 shares
Warrants Issued November 18, 2020, Outstanding
Common
Warrants (in shares)	386
Warrants Issued March 9, 2023, Outstanding
Common
Warrants (in shares)	996,264

LOSS PER SHARE - Narrative (Det

LOSS PER SHARE - Narrative (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Potentially dilutive option awards excluded from earnings per share calculation (in shares)	1,600	94

FAIR VALUE MEASUREMENTS - Narra

FAIR VALUE MEASUREMENTS - Narrative (Details) - Fair Value, Recurring - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Assets, fair value disclosure	$ 0	$ 0
Liabilities, fair value disclosure	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Asset

FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended
	Mar. 13, 2023	Jun. 30, 2023	Jun. 14, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Fair Value of Warrant Liability [Roll Forward]
Loss on issuance of warrants	$ (10,424)	$ 0		$ 0	$ (10,424)	$ 0
(Loss) gain from change in fair value of warrant liabilities		896	$ 2,149	$ 0	(2,149)	$ 0
Pre-Funded Warrant Liability
Fair Value of Warrant Liability [Roll Forward]
Loss on issuance of warrants		(900)			(900)
Series-A Warrant Liability
Fair Value of Warrant Liability [Roll Forward]
Loss on issuance of warrants		$ 2,100			$ 2,100
Fair Value, Recurring | Pre-Funded Warrant Liability | Warrant Liability
Fair Value of Warrant Liability [Roll Forward]
Measurement at March 13, 2023			15,940
Change in fair value			(996)
Measurement at June 14, 2023	15,940		14,944
Fair Value, Recurring | Series-A Warrant Liability | Warrant Liability
Fair Value of Warrant Liability [Roll Forward]
Measurement at March 13, 2023			10,484
Change in fair value			(1,153)
Measurement at June 14, 2023	$ 10,484		$ 9,331

BALANCE SHEET AND OTHER INFOR_3

BALANCE SHEET AND OTHER INFORMATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Inventory [Line Items]
Restricted cash	$ 676		$ 676		$ 676
Depreciation included in cost of sales	57	$ 57	90	$ 117
Amortization of intangible assets			68	295
Operating lease, expense	25	126	154	256
Hardware and subscription revenue
Inventory [Line Items]
Inventory recognized as cost of sales	103	176	314	232
Depreciation included in cost of sales	2	26	11	52
Amortization of intangible assets	$ 28	$ 20	$ 54	$ 22

BALANCE SHEET AND OTHER INFOR_4

BALANCE SHEET AND OTHER INFORMATION - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
MedCenter hardware	$ 7,924	$ 8,154
Spare parts	2,141	663
Total inventory	$ 10,065	$ 8,817

BALANCE SHEET AND OTHER INFOR_5

BALANCE SHEET AND OTHER INFORMATION - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid MedCenter inventory	$ 0	$ 1,359
Prepaid insurance	467	921
Other	244	289
Total prepaid expenses and other current assets	$ 711	$ 2,569

BALANCE SHEET AND OTHER INFOR_6

BALANCE SHEET AND OTHER INFORMATION - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total historical cost	$ 4,597	$ 4,212
Accumulated depreciation	(3,865)	(3,774)
Total property, plant and equipment, net	$ 732	438
MedCenter equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Total historical cost	$ 1,530	1,357
IT equipment
Property, Plant and Equipment [Line Items]
Total historical cost	$ 2,002	1,908
IT equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	1 year
IT equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total historical cost	$ 316	316
General plant and equipment
Property, Plant and Equipment [Line Items]
Total historical cost	$ 376	373
General plant and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
General plant and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Total historical cost	$ 332	217
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Total historical cost	$ 36	36
Construction-in-process
Property, Plant and Equipment [Line Items]
Total historical cost	$ 5	$ 5

BALANCE SHEET AND OTHER INFOR_7

BALANCE SHEET AND OTHER INFORMATION - Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 6,851	$ 6,591
Total accumulated amortization	(6,194)	(6,140)
Total intangible assets, net	657	451
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	3,857	3,857
Total accumulated amortization	(3,857)	(3,857)
Software
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	2,337	2,200
Total accumulated amortization	(1,801)	(1,749)
Website and mobile application
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	534	534
Total accumulated amortization	(534)	(534)
Other
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	123	0
Total accumulated amortization	$ (2)	$ 0

BALANCE SHEET AND OTHER INFOR_8

BALANCE SHEET AND OTHER INFORMATION - Leases, Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Total lease assets	Total lease assets
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Total lease assets	Total lease assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current portion of lease obligations	Current portion of lease obligations
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term portion of lease obligations	Long-term portion of lease obligations
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current portion of lease obligations	Current portion of lease obligations
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term portion of lease obligations	Long-term portion of lease obligations
Assets
Operating	$ 499	$ 620
Finance	202	4
Total lease assets	701	624
Operating:
Current	173	241
Long-term	382	441
Finance:
Current	35	5
Long-term	168	0
Total lease liabilities	$ 758	$ 687

BALANCE SHEET AND OTHER INFOR_9

BALANCE SHEET AND OTHER INFORMATION - Additional Lease Information (Details)	Jun. 30, 2023	Dec. 31, 2022
Finance leases:
Weighted-average remaining lease term (years)	4 years 6 months	6 months
Weighted-average discount rate	11.50%	6%
Operating leases:
Weighted-average remaining lease term (years)	3 years 4 months 24 days	3 years 7 months 6 days
Weighted-average discount rate	6.10%	7.30%

BALANCE SHEET AND OTHER INFO_10

BALANCE SHEET AND OTHER INFORMATION - Leases, Operating Lease Liability Maturity (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2023	$ 135
2024	148
2025	152
2026	157
2027	37
Total operating lease payments	629
Less: present value discount	(74)
Total operating leases	$ 555

BALANCE SHEET AND OTHER INFO_11

BALANCE SHEET AND OTHER INFORMATION - Leases, Finance Lease Liability Maturity (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2023	$ 29
2024	58
2025	58
2026	58
2027	58
Total finance lease payments	261
Less: imputed interest	(58)
Total finance leases	$ 203

DEBT - Schedule of Debt (Detail

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Term loan	$ 2,002
Long-term debt, net	1,506	$ 4,798
Term loan | Secured Debt
Debt Instrument [Line Items]
Term loan	2,002	5,182
Term loan issuance costs, net	$ (496)	$ (384)

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Debt Liabilities (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Debt Disclosure [Abstract]
Remaining period in 2023	$ 0
2024	668
2025	1,000
2026	334
Total debt	$ 2,002

DEBT - Narrative (Details)

DEBT - Narrative (Details) - USD ($) $ in Thousands		6 Months Ended
	Feb. 10, 2023	Jun. 30, 2023	Mar. 29, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Payment of assets sale	$ 3,400
Final payment	400
Prepayment	$ 3,000
Cash in bank accounts		$ 14,359		$ 11,444
SVB Warrants
Debt Instrument [Line Items]
Percent threshold of dollar value of total accounts held at financial institutions			50%
Cash in bank accounts		9,700
Other Financial Institution
Debt Instrument [Line Items]
Cash in bank accounts		$ 5,300
Term loan | Secured Debt
Debt Instrument [Line Items]
Debt instrument, interest rate floor		7.25%
Interest rate at end of period		12.25%
Term loan | Secured Debt | Prime Rate
Debt Instrument [Line Items]
Variable interest rate spread		4%

SHARE-BASED COMPENSATION - Shar

SHARE-BASED COMPENSATION - Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-based compensation	$ 381	$ 612	$ 999	$ 1,176

SHARE-BASED COMPENSATION - Narr

SHARE-BASED COMPENSATION - Narrative (Details) - USD ($) shares in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense remaining to be recognized	$ 1.5
Weighted average recognition period (in years)	2 years
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate shares of common stock available for grant (in shares)	93	46
2022 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate shares of common stock available for grant (in shares)	22	4
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense remaining to be recognized	$ 0.9
Weighted average recognition period (in years)	1 year 6 months

SHARE-BASED COMPENSATION - Opti

SHARE-BASED COMPENSATION - Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Number of Awards
Outstanding awards at beginning of period (in shares) | shares	87,995
Granted (in shares) | shares	43,637
Exercised/released (in shares) | shares	0
Expired (in shares) | shares	(62)
Forfeited (in shares) | shares	(28,362)
Outstanding awards at end of period (in shares) | shares	103,208
Awards vested and exercisable (in shares) | shares	37,186
Awards vested and unvested exercisable (in shares) | shares	37,186
Awards vested and expected to vest (in shares) | shares	100,542
Weighted Average Exercise Price
Outstanding awards at beginning of period (in USD per share)	$ 94.64
Granted (in USD per share)	15.25
Exercised/released (in USD per share)	0
Expired (in USD per share)	622.69
Forfeited (in USD per share)	95.49
Outstanding at end of period (in USD per share)	60.66
Weighted average exercise price of awards vested and exercisable (in USD per share)	107.53
Weighted average exercise price of awards vested and unvested exercisable (in USD per share)	107.53
Weighted average exercise price of awards vested and expected to vest (in USD per share)	61.91
Weighted Average Fair Value
Outstanding at beginning of period (in USD per share)	57.26
Granted (in USD per share)	11.66
Exercised/released (in USD per share)	0
Expired (in USD per share)	372.66
Forfeited (in USD per share)	53.27
Outstanding at end of period (in USD per share)	39.03
Weighted average fair value of awards vested and exercisable (in USD per share)	66.14
Weighted average fair value of awards vested and unvested exercisable (in USD per share)	66.14
Weighted average fair value of awards vested and expected to vest (in USD per share)	$ 39.79
Weighted Average Remaining Contractual Life (Years)
Outstanding, end of period	9 years 1 month 9 days
Vested and exercisable, end of the period	8 years 2 months 4 days
Vested and unvested exercisable, end of the period	8 years 2 months 4 days
Vested and expected to vest, end of the period	9 years 1 month 2 days
Aggregate Intrinsic Value
Outstanding, at December 31, 2022 | $	$ 0
Granted | $	1
Exercised/Released | $	0
Expired | $	0
Forfeited | $	0
Outstanding, end of period, at June 30, 2023 | $	0
Aggregate intrinsic value of awards vested and exercisable | $	0
Aggregate intrinsic value of awards vested and unvested exercisable | $	0
Aggregate intrinsic value of awards vested and expected to vest | $	$ 0

SHARE-BASED COMPENSATION - RSU

SHARE-BASED COMPENSATION - RSU Activity (Details) - Restricted Stock Units (RSUs)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Number of Awards
Outstanding awards at beginning of period (in shares) | shares	47,531
Granted (in shares) | shares	0
Exercised/Released (in shares) | shares	(9,702)
Cancelled/Forfeited (in shares) | shares	(18,983)
Expired (in shares) | shares	0
Outstanding awards at end of period (in shares) | shares	18,846
Vested, outstanding shares (in shares) | shares	0
Weighted Average Exercise Price
Unvested outstanding, beginning of period (in USD per share)	$ 0
Granted (in USD per share)	0
Exercised/Released (in USD per share)	15.84
Cancelled/Forfeited (in USD per share)	0
Expired (in USD per share)	0
Unvested outstanding, end of period (in USD per share)	0
Vested, outstanding shares (in USD per share)	0
Weighted Average Fair Value
Unvested outstanding, beginning of period (in USD per share)	65.30
Granted (in USD per share)	0
Exercised/Released (in USD per share)	77.02
Cancelled/Forfeited (in USD per share)	62.67
Expired (in USD per share)	0
Unvested outstanding, end of period (in USD per share)	61.99
Vested, outstanding shares (in USD per share)	$ 0
Weighted Average Remaining Contractual Life (Years)
Weighted average remaining contractual life	14 years 3 months 14 days

WARRANTS - Narrative (Details)

WARRANTS - Narrative (Details) $ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

Jul. 31, 2023

Jul. 14, 2023

Jun. 14, 2023 USD ($)

Mar. 13, 2023 USD ($) $ / shares shares

Mar. 09, 2023 USD ($) $ / shares shares

Jul. 01, 2022 USD ($) $ / shares shares

Apr. 04, 2022 USD ($) $ / shares shares

Jun. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

Jun. 16, 2023 $ / shares shares

Feb. 10, 2023 USD ($) $ / shares shares

Mar. 30, 2022 closing $ / shares shares

Class of Warrant or Right [Line Items]

Stock split, conversion ratio

0.0200

Proceeds from issuance of warrants in private placement

$ 15,999

$ 37,201

Gain (loss) on issuance of warrants

$ (10,424)

$ 0

$ 0

(10,424)

$ 0

Private Placement

Class of Warrant or Right [Line Items]

Number of shares authorized to be sold (in shares) | shares

942,000

Number of shares called by warrants (in shares) | shares

470,000

Number of closings | closing

2

Sale of stock (in USD per share) | $ / shares

$ 50.13

Proceeds from issuance of warrants in private placement

$ 16,000

Warrants Issued April 2022 | Private Placement

Class of Warrant or Right [Line Items]

Number of shares called by warrants (in shares) | shares

376,000

Number of shares sold or expected to be sold (in shares) | shares

75,200

Gross proceeds from private placement

$ 40,000

Fair value

$ 9,200

Term of warrants (in years)

5 years

Exercise price of warrants issued (in USD per share) | $ / shares

$ 62.50

Warrants Issued July 2022 | Private Placement

Class of Warrant or Right [Line Items]

Number of shares called by warrants (in shares) | shares

94,000

Number of shares sold or expected to be sold (in shares) | shares

188,000

Gross proceeds from private placement

$ 10,000

Fair value

$ 4,500

Term of warrants (in years)

5 years

Exercise price of warrants issued (in USD per share) | $ / shares

$ 62.50

SVB Warrants

Class of Warrant or Right [Line Items]

Number of shares called by warrants (in shares) | shares

5,400

4,000

Fair value

$ 57

Exercise price of warrants issued (in USD per share) | $ / shares

$ 10.25

$ 16.37

Pre-Funded Warrant Liability

Class of Warrant or Right [Line Items]

Number of shares called by warrants (in shares) | shares

996,300

Fair value

$ 14,900

$ 15,900

Exercise price of warrants issued (in USD per share) | $ / shares

$ 0.05

Stock exercise price (in USD per share) | $ / shares

$ 16.06

Proceeds from issuance of warrants in private placement

$ 16,000

Percentage of common stock outstanding prior to offering

19.99%

Gain (loss) on issuance of warrants

(900)

(900)

Pre-Funded Warrant Liability | Private Placement

Class of Warrant or Right [Line Items]

Number of shares called by warrants (in shares) | shares

49,813,198

Exercise price of warrants issued (in USD per share) | $ / shares

$ 0.001

Series-A Warrant Liability

Class of Warrant or Right [Line Items]

Number of shares called by warrants (in shares) | shares

996,300

Fair value

$ 9,300

$ 10,500

Exercise price of warrants issued (in USD per share) | $ / shares

$ 19.27

Gain (loss) on issuance of warrants

$ 2,100

$ 2,100

Series-A Warrant Liability | Private Placement

Class of Warrant or Right [Line Items]

Number of shares called by warrants (in shares) | shares

49,813,198

Exercise price of warrants issued (in USD per share) | $ / shares

$ 0.38544

Subsequent Event

Class of Warrant or Right [Line Items]

Stock split, conversion ratio

0.0200

0.0200

WARRANTS - Valuation of Warrant

WARRANTS - Valuation of Warrants Issued (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares
SVB Warrants
Class of Warrant or Right [Line Items]
Grant date, market price (in USD per share)	$ 16
Grant date, exercise price (in USD per share)	$ 16.37
Grant date, term (year)	12 years
Grant date, volatility	85%
Grant date, risk free rate	3.68%
Pre-Funded Warrant Liability
Class of Warrant or Right [Line Items]
Grant date, market price (in USD per share)	$ 16
Grant date, exercise price (in USD per share)	$ 0.05
Grant date, volatility	85%
Grant date, risk free rate	3.70%
Market price (in USD per share)	$ 15
Exercise price (in USD per share)	$ 0.05
Volatility	82%
Risk Free Rate	3.90%
Series-A Warrant Liability
Class of Warrant or Right [Line Items]
Grant date, market price (in USD per share)	$ 16
Grant date, exercise price (in USD per share)	$ 19.27
Grant date, term (year)	5 years
Grant date, volatility	85%
Grant date, risk free rate	3.68%
Market price (in USD per share)	$ 15
Exercise price (in USD per share)	$ 19.27
Term (Years)	4 years 8 months 12 days
Volatility	82%
Risk Free Rate	4.10%

DISCONTINUED OPERATIONS - Sched

DISCONTINUED OPERATIONS - Schedule of Income from Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expense:
Loss from discontinued operations	$ (295)	$ (6,301)	$ (5,067)	$ (13,414)
Pharmacy Services Business | Discontinued Operations, Disposed of by Sale
Revenue:
Total revenue	0	10,641	3,834	19,490
Cost of products sold and services:
Total cost of products sold and services	0	9,931	3,581	18,412
Operating expense:
Pharmacy operations	157	3,450	1,883	7,170
General and administrative	141	1,242	711	2,560
Selling and marketing	0	2,253	845	4,457
Research and development	0	63	0	299
Total operating expense	298	7,008	3,439	14,486
Operating loss	(298)	(6,298)	(3,186)	(13,408)
Loss from sale and disposition of net assets, and reorganization expenses, net	0	0	(1,885)	0
Interest expense	3	(3)	4	(6)
Loss from discontinued operations	$ (295)	$ (6,301)	$ (5,067)	$ (13,414)

DISCONTINUED OPERATIONS - Narra

DISCONTINUED OPERATIONS - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on disposal of net assets from discontinued operations	$ 319	$ 0
Pharmacy Services Business | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group cash used in operating activities	987	14,400
Disposal group cash provided by (used in) investing activities	212	(428)
Disposal group cash used in financing activities	47	41
Disposal group depreciation and amortization	$ 895	$ 673

DISCONTINUED OPERATIONS - Asset

DISCONTINUED OPERATIONS - Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Carrying amounts of major classed of assets included as part of discontinued operations:
Current assets from discontinued operations	$ 946	$ 4,842
Long-term assets from discontinued operations	729	2,837
Total long-term assets from discontinued operations
Total current liabilities from discontinued operations	1,512	2,794
Discontinued Operations, Disposed of by Sale | Pharmacy Services Business
Carrying amounts of major classed of assets included as part of discontinued operations:
Accounts receivable, net	946	1,805
Prepaid expenses and other current assets	0	94
Inventories	0	2,943
Current assets from discontinued operations	946	4,842
Intangible assets, net	0	14
Property plant and equipment, net	0	1,194
Right-of-use assets	622	1,461
Other assets	107	168
Long-term assets from discontinued operations	729	2,837
Total long-term assets from discontinued operations
Accounts payable	162	857
Accrued liabilities	954	641
Accrued payroll and benefits	81	834
Current portion of lease obligations	315	462
Total current liabilities from discontinued operations	1,512	2,794
Long-term portion of lease obligations	651	1,128
Total long-term liabilities from discontinued operations	$ 651	$ 1,128

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details)		Jul. 31, 2023 $ / shares shares	Jul. 14, 2023	Jun. 14, 2023 $ / shares	Jul. 30, 2023 shares	Jun. 30, 2023 $ / shares shares		Dec. 31, 2022 $ / shares shares
Class of Stock [Line Items]
Stock split, conversion ratio				0.0200
Common shares, outstanding (in shares)	[1]					1,613,870		1,603,394
Common shares, authorized (in shares)	[1]					300,000,000		300,000,000
Common shares, par value (in USD per share) | $ / shares				$ 0.001		$ 0.001	[1]	$ 0.001	[1]
Subsequent Event
Class of Stock [Line Items]
Stock split, conversion ratio		0.0200	0.0200
Common shares, outstanding (in shares)		1,613,870			80,693,517
Capital stock, authorized (in shares)		310,000,000
Common shares, authorized (in shares)		300,000,000
Common shares, par value (in USD per share) | $ / shares		$ 0.001
Preferred stock, authorized (in shares)		10,000,000
Preferred stock, par value (in USD per share) | $ / shares		$ 0.001
[1]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details)	Jul. 31, 2023 $ / shares	Jul. 14, 2023	Jun. 14, 2023 $ / shares	Jun. 30, 2023 $ / shares	[1]	Dec. 31, 2022 $ / shares	[1]
Subsequent Event [Line Items]
Common shares, par value (in USD per share)			$ 0.001	$ 0.001		$ 0.001
Stock split, conversion ratio			0.0200
Subsequent Event
Subsequent Event [Line Items]
Common shares, par value (in USD per share)	$ 0.001
Stock split, conversion ratio	0.0200	0.0200
Minimum
Subsequent Event [Line Items]
Stock split, conversion ratio			0.0333
Maximum
Subsequent Event [Line Items]
Stock split, conversion ratio			0.0125
[1]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.